Drug Profile
Research programme: autoantibody therapeutics - ImmunoQure AG
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator ImmunoQure AG
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Autoimmune-disorders in Germany (Parenteral)
- 02 Oct 2019 ImmunoQure AG signs a collaboration agreement with Memo Therapeutics for the usage of the latter's DROPZYLLATM technology platform in the development of autoantibody therapeutics in Autoimmune disorders
- 18 Jul 2016 Early research in Autoimmune disorders in Germany (Parenteral)